Linked Life Data

12101108

Source:http://linkedlifedata.com/resource/pubmed/id/12101108

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2002-7-8
pubmed:abstractText
The aromatase enzyme converts androgens to estrogens and is the therapeutic target for aromatase inhibitors in postmenopausal patients with estrogen receptor-positive metastatic breast cancer. Third-generation inhibitors such as letrozole are being considered as potential prophylactic agents for breast cancer. The rationale for their preventive application would be aided by knowledge of their effects on the normal breast and on other estrogen-dependent processes such as bone and lipid metabolism. Thirty-two women without active breast disease were recruited to 3-month treatment with letrozole (2.5 mg/day). Core-cut biopsies from the breast and blood samples were collected before and at the end of treatment. Plasma estradiol levels were markedly suppressed in all but two patients, who were excluded from the efficacy assessment. There was no significant change in the proliferation marker Ki67 (mean change, -23%; 95% confidence interval, -50% to +23%) or estrogen receptor in breast epithelial cells with treatment. Similarly, there were no significant changes in plasma levels of insulin-like growth factor I or lipid profiles. However, there was a significant increase (25%) in the levels of the bone resorption marker C-telopeptide crosslinks (CTx). We conclude that any prophylactic effect of letrozole is not likely to be dependent on antiproliferative effects on normal breast. Studies in healthy patients will need to recognize the potential for enhanced bone resorption.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1055-9965
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
614-21
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12101108-Administration, Oral, pubmed-meshheading:12101108-Aged, pubmed-meshheading:12101108-Biological Markers, pubmed-meshheading:12101108-Biopsy, Needle, pubmed-meshheading:12101108-Breast Diseases, pubmed-meshheading:12101108-Breast Neoplasms, pubmed-meshheading:12101108-Cell Division, pubmed-meshheading:12101108-Confidence Intervals, pubmed-meshheading:12101108-Drug Administration Schedule, pubmed-meshheading:12101108-Enzyme Inhibitors, pubmed-meshheading:12101108-Epithelial Cells, pubmed-meshheading:12101108-Female, pubmed-meshheading:12101108-Humans, pubmed-meshheading:12101108-Immunohistochemistry, pubmed-meshheading:12101108-Ki-67 Antigen, pubmed-meshheading:12101108-Middle Aged, pubmed-meshheading:12101108-Nitriles, pubmed-meshheading:12101108-Odds Ratio, pubmed-meshheading:12101108-Postmenopause, pubmed-meshheading:12101108-Primary Prevention, pubmed-meshheading:12101108-Probability, pubmed-meshheading:12101108-Receptors, Estrogen, pubmed-meshheading:12101108-Reference Values, pubmed-meshheading:12101108-Sensitivity and Specificity, pubmed-meshheading:12101108-Statistics, Nonparametric, pubmed-meshheading:12101108-Triazoles
pubmed:year
2002
pubmed:articleTitle
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
pubmed:affiliation
Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't